Adamax ge 'nar sintético heptapéptido derivado ar Semax; ar secuencia ar aminoácidos específica komongu Ac — MEHFPG — AG — NH₂.
Semax hä xkagentho, 'nar fragmento ar hormona adrenocorticotrópica (ACTH), posee potentes propiedades neurotróficas ne mejoras cognitivas.
limitaciones estructurales mbo Semax conducen da limitaciones significativas ár nzaki made ne ya dätä nt'ot'e cruzar ar barrera hephráfamika.
pa aliviar gi limitaciones, ya científicos introdujeron 'nar Hmunts'i voluminoso adamantilacetato a través de enlace covalente ja ar extremo ar carboxilo.
nuna nyokwi significativamente mejoró ar propiedades farmacocinéticas ar molécula peptídica.
Nthuts'i ñut'i nuna ar mitad proporciona kasu̲ ar resistencia nxo̲ge ma 'me̲fa degradación enzimática; pa retención ar nt'ot'e activa ar Adamax mbo komongu ar prolonga grandemente.
mäs emocionante, the previously mentioned ‘ingenious’ design promotes an increase in efficiency with which the peptide crosses said barrier, and enhanced specificity and selectivity is achieved.
Compromising no biological activity, all known effects of semax are either maintained or enhanced.
Secuencia
Ac-MEHFPGP-Adam-NH2
'bede ya CAS
/
Fórmula molecular
C50H68N10O12S
Be̲xu molecular
1033.212
Research Of Adamax:
1.Therapeutic Efficacy and Clinical Potential
Clinical trials have shown Adamax to outperform Semax in promoting the growth and protection of brain derived neurotrophic factor (BDNF) and to a point nerve growth factor (NGF).
Replacing Semax as a therapeutic agent, particularly for psychiatric disorders or social cognition enhancement, is a very real possibility.
2.Cognitive Enhancement (Intelligence being a subset)
Direct stimulation of BDNF upregulation is Adamax’s primary function.
Neuronal cell activity, new neuron generation/differentiation and all associated synaptic improvements are what the research is currently focused on.
Hippocampal and prefrontal cortex activity is also increased.
Long term experimental groups have and will continue to show, quantifiably, superior memory and learning abilities.
3.Neuroprotective Effects
Adamax’s cognitive enhancement and intelligence-boosting functions originate not only from its direct promotion of neural cell growth, but also from demonstrable neuroprotective properties.
Effective reduction of cerebral infarction areas in stroke patients has been demonstrated; stimulation and subsequent recovery of various necrotic cells is another key aspect of this neuroprotection.
Reducing excitotoxicity and providing near-constant antioxidant effects are additional, well-documented activities.
Positioning itself within this realm, Adamax holds much promise as a true therapeutic agent for neurodegenerative disorders – Alzheimer’s being the prime example, Parkinson’s following closely behind.
4.Stress and Anxiety Relief
Adamax enhances the human ability to adapt to environmental changes; the brain itself must rapidly adjust to, and resist, a variety of physiological stressors resulting from these quick environmental shifts.
Maintaining some form of homeostasis is the end goal.
Modulation of the hypothalamic-pituitary-adrenal (HPA) eje is central to this process, increasing or decreasing the appropriate release of neurotransmitters, all lesser ‘stress responses’ being suppressed.
Anxiolytic effects are a primary benefit – drowsiness and cognitive impairment (the near universal side effects of traditional anxiolytics) are completely avoided.
Enhancing cognitive function during any form of anxiety relief is what makes Adamax particularly alluring to researchers and patients alike.
COA
HPLC
MS
